Heart of the Matter

More than 500,000 Australians are currently living with heart valve disease, with many hundreds of thousands more estimated to be living with it undiagnosed. Australian company Anteris Technologies works on creating innovative solutions to this widespread and harmful condition.

Anteris Technologies has focused on applying the ‘ADAPT Tissue Treatment’ core tissue engineering method to treat aortic stenosis. But when Wayne Paterson became CEO and Managing Director of the pioneering company in June 2020, he quickly realized that the full value of the technology wasn’t being unlocked.

“The ADAPT Tissue Treatment technology has 10 years of clinical evidence demonstrating its ability to remove inflammation triggers at the same time as making the tissue highly resistant to calcification,” Paterson tells The CEO Magazine.

“But when I joined Anteris, the company was only applying this technology to the surgical repair space, a market worth only approximately A$50 million [US$33.4 million] globally. I was therefore presented with the opportunity to take ADAPT and to create numerous new innovations from that base.”

This shift led to the development of a transcatheter heart valve, which is the only 3D single-piece valve design that is anatomically correct and therefore creates less mechanical stress and optimal hemodynamics.

“I saw an enormous unmet need and opportunity to deliver patients and physicians with new solutions. That decision now allows Anteris to compete in a A$15 billion [US$10 billion] space,” Paterson says.

Never Miss a Beat

Due to the company continually delivering on its milestones, Anteris has seen its share price more than double, and several key strategic investors join the register.

Over the next few years, Paterson aims to continue the progress that has been made in the clinical development of the Anteris transcatheter heart valve, with gaining regulatory approvals for the innovation in the treatment of aortic stenosis being essential.

Once this has been achieved, he hopes to “obtain market access approvals in multiple countries and make sure the company is globally prepared for the imminent product launch”.

High levels of investment in research and development activities are also on the agenda to enable the clinical road map to be achieved on time. A number of other projects are also being embraced as Anteris further develops its clinical studies and increases its commercial and manufacturing capacity.

“The development of surgically implantable prosthetic heart valves made from ADAPT-treated pericardium is one of those opportunities,” he says. “That’s a multibillion-dollar space that we would be very competitive in.”

But moves like this will require Anteris to scale up its current capacity. “This means upscaling key aspects of the business, including manufacturing, sales forces, management systems and internal processes required to continue down our commercialization and growth path,” Paterson explains.

Scale and Adapt

“As always, with a company that’s growing quickly, or with any young organization, we are working through challenges associated with structures, sharpening processes and ensuring everybody’s aligned,” he says.

“There are certainly challenges, but I’ve lived through those before in other organizations, so it’s nothing that my management team and I can’t handle.”

Very early on the company implemented what is called AORTIC values, and Paterson believe these are key to its success.

“They start with Accountability, leading to Objectivity, Respect, Teamwork, Integrity and Courage. These are powerful descriptors that set the tone for our high-performing organizational culture,” he explains.

Unlike competitors who are typically global businesses with a place in the market due to the acquisition of smaller companies, Anteris’s core technologies are proprietary innovations that have taken place in Australian labs and are informed by real-world physician experiences.

“Our ADAPT tissue science has been widely used to reconstruct the heart of thousands of congenital heart disease patients worldwide, proving that the performance characteristics are consistent with durability and longevity in the most challenging patients,” Paterson concludes.